Novo Nordisk: What the Company Makes and Why It Matters

Novo Nordisk is a Danish pharmaceutical company best known for prescription diabetes and obesity medicines, including Ozempic, Wegovy, and Rybelsus. It is a research-based drugmaker headquartered near Copenhagen, not a supplement brand or a peptide vendor. Its medicines are sold by prescription only, and its GLP-1 products have kept the company in health and business headlines since 2021.

What Novo Nordisk Does Today

Novo Nordisk concentrates on chronic metabolic disease plus a small group of rare conditions. The business is organized into three therapeutic areas.

• Diabetes care: insulins, GLP-1 receptor agonists, and injection devices used by people with type 1 and type 2 diabetes.
• Obesity care: prescription weight-management medicines such as Wegovy and Saxenda.
• Rare disease: hemophilia therapies, growth hormone treatment, and other specialty medicines.

The company was formed through the 1989 merger of two Danish insulin manufacturers that trace their roots to the 1920s. Novo Nordisk spent decades as the world's largest insulin producer before GLP-1 medicines became its main growth engine.

The Main Novo Nordisk Products

Investors and patients alike track novo nordisk products by therapeutic area rather than by brand, because several brands use the same molecule at different doses and for different indications.

Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus, so the three brands are often discussed together even though the FDA approved them for different purposes. Doses and titration schedules are not interchangeable between brands.

Why GLP-1 Medicines Changed the Company

GLP-1 receptor agonists mimic a gut hormone that slows stomach emptying and signals fullness to the brain. Wegovy's 2021 approval for chronic weight management turned a diabetes-focused manufacturer into a consumer name almost overnight, and demand quickly outran manufacturing capacity.

The shortage had a side effect: compounding pharmacies began producing their own semaglutide. Federal regulators declared the semaglutide shortage resolved in early 2025 and set deadlines for those large-scale copies to stop, although litigation over compounding continued afterward.

Novo Nordisk's parent holding company also bought contract manufacturer Catalent in a $16.5 billion deal that closed in late 2024, largely to secure more fill-finish capacity for Wegovy pens. Even with that expansion, the company lowered its 2025 sales outlook as competition and pricing pressure built up.

The GLP-1 market in the United States is effectively a two-company race.

Both companies sell weekly injections approved for type 2 diabetes and for chronic weight management. Head-to-head trial data have favored tirzepatide on average weight loss, while semaglutide has the longer real-world track record and a broader set of approved formulations.

Novo Nordisk vs. Novo Peptides: A Common Name Mix-Up

Novo Nordisk has no connection to the gray-market sellers that use similar names. Rising search interest in novo peptides telegram points to a separate, largely unregulated market where peptides are labeled for laboratory research and then resold to individuals.

Two peptides that dominate that market are BPC-157 and TB-500. BPC-157 is not FDA-approved for human use in the United States, and no pharmacy dispenses it as a legal prescription medicine. That means any specific figure, including a bpc-157 dosage chart by weight, comes from self-reported forum posts rather than supervised clinical trials.

People searching where to buy bpc-157 peptide should assume the product is unverified. Independent testing of gray-market peptide vials has repeatedly found mislabeled contents, wrong concentrations, and bacterial contamination. None of these products are Novo Nordisk medicines, and none have been reviewed by the FDA for safety or purity.

Pricing, Access, and Safety

Every Novo Nordisk product sold in the United States requires a prescription. List prices for GLP-1 medicines run into the hundreds of dollars per month, and the company introduced self-pay pricing programs in 2025 to lower out-of-pocket costs for people without insurance coverage.

Common side effects of GLP-1 medicines include nausea, vomiting, diarrhea, and constipation, especially during dose increases. Rarer but serious risks include pancreatitis and gallbladder disease, and the labels carry a boxed warning about thyroid C-cell tumors observed in rodents.

Anyone considering semaglutide or liraglutide should talk with a healthcare professional about their personal risk profile. Compounded versions are not FDA-approved and should not be treated as equivalent to the branded products.

Key Takeaways

• Novo Nordisk is a Danish pharmaceutical company focused on diabetes, obesity, and rare diseases.
• Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus, and the three brands are approved for different uses.
• Novo Nordisk is not affiliated with Novo Peptides or any gray-market peptide seller.
• BPC-157 is not FDA-approved for human use in the United States.
• GLP-1 medicines require a prescription and should be used under medical supervision.